Studies of GPER in human tumours have primarily focused on sex hormone-dependent cancers, with contradictory results, which may in part be due to the wide variety of polyclonal antibodies from commercial and non-commercial sources that have been used in these studies. This evidence concerns the gene GPER1 and neoplasm.